id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
CDC-2020-0046-0147,CDC,CDC-2020-0046,"Hazardous Drugs: NIOSH List of Hazardous Drugs in Healthcare Settings, 2024 and Final Reevaluation Determinations for Liraglutide and Pertuzumab",Notice,,2024-12-20T05:00:00Z,2024,12,2024-12-20T05:00:00Z,,2024-12-20T12:11:45Z,2024-30456,0,0,09000064868812b4
CDC-2020-0046-0141,CDC,CDC-2020-0046,Request for Public Comment on NIOSH Initial Recommendations To Change the Status of Liraglutide and Pertuzumab on the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings,Notice,,2024-01-16T05:00:00Z,2024,1,2024-01-16T05:00:00Z,2024-02-16T04:59:59Z,2024-02-16T02:00:32Z,2024-00693,0,0,090000648639cec4
CDC-2020-0046-0138,CDC,CDC-2020-0046,"Hazardous Drugs: Procedures for Developing the NIOSH List of Hazardous Drugs in Healthcare Settings and Managing Hazardous Drug Exposures: Information for 
Healthcare Settings",Notice,,2023-04-27T04:00:00Z,2023,4,2023-04-27T04:00:00Z,,2023-04-27T12:02:49Z,2023-08900,0,0,090000648598f57e
CDC-2020-0046-0029,CDC,CDC-2020-0046,"Hazardous Drugs: Draft NIOSH List of Hazardous Drugs in Healthcare Settings, 2020; Procedures; and Risk Management Information; Extension of Comment Period",Notice,,2020-06-19T04:00:00Z,2020,6,2020-06-19T04:00:00Z,2020-07-31T03:59:59Z,2020-08-07T01:03:59Z,2020-13278,0,0,09000064846f98da
CDC-2020-0046-0001,CDC,CDC-2020-0046,"Hazardous Drugs: Draft NIOSH List of Hazardous Drugs in Healthcare Settings, 2020; Procedures; and Risk Management Information.",Notice,,2020-05-01T04:00:00Z,2020,5,2020-05-01T04:00:00Z,2020-07-31T03:59:59Z,2024-01-16T12:46:12Z,2020-09332,0,0,090000648452f1a3